NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Forecast, Price & News

$1.86

0.00 (0.00%)

(As of 05/31/2023 ET)

Compare

Today's Range: $1.80
▼
$1.90
50-Day Range: $1.43
▼
$1.97
52-Week Range: $1.18
▼
$4.08

Volume: 44,763 shs
Average Volume: 98,231 shs
Market Capitalization: $67.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Black Diamond Therapeutics (NASDAQ:BDTX) Stock

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BDTX Stock News Headlines

May 25, 2023 | finance.yahoo.com

Black Diamond Therapeutics Insider Ups Holding By 82% During Year

May 18, 2023 | finance.yahoo.com

Black Diamond Therapeutics Insider Ups Holding By 82% During Year \

May 31, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

May 14, 2023 | americanbankingnews.com

Wedbush Weighs in on Black Diamond Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:BDTX)

May 13, 2023 | americanbankingnews.com

FY2027 EPS Estimates for Black Diamond Therapeutics, Inc. Increased by Analyst (NASDAQ:BDTX)

May 11, 2023 | msn.com

Wedbush Reiterates Black Diamond Therapeutics (BDTX) Neutral Recommendation

May 9, 2023 | markets.businessinsider.com

Berenberg Bank Remains a Buy on Black Diamond Therapeutics (BDTX)

May 9, 2023 | finanznachrichten.de

Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 9, 2023 | finance.yahoo.com

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 18, 2023 | finance.yahoo.com

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

April 17, 2023 | tmcnet.com

Black Diamond Therapeutics Presents Trial in Progress Poster

April 17, 2023 | finance.yahoo.com

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

March 13, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Fulcrum Therapeutics (FULC) and Black Diamond Therapeutics (BDTX)

March 9, 2023 | benzinga.com

Black Diamond Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results.

March 9, 2023 | msn.com

Black Diamond Therapeutics GAAP EPS of -$0.59 beats by $0.04

March 9, 2023 | finance.yahoo.com

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 27, 2023 | finance.yahoo.com

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

February 10, 2023 | morningstar.com

Black Diamond Therapeutics Inc Ordinary Shares

January 19, 2023 | finance.yahoo.com

private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week

January 5, 2023 | finance.yahoo.com

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 19, 2022 | finance.yahoo.com

Black Diamond Therapeutics Announces Changes to Board of Directors

December 12, 2022 | finance.yahoo.com

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

December 9, 2022 | finance.yahoo.com

Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

December 9, 2022 | finance.yahoo.com

Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) recent US$17m market cap decline means a loss of US$21k for insiders who bought this year

December 6, 2022 | seekingalpha.com

Black Diamond Therapeutics: Selling For Large Discount To Cash

November 8, 2022 | finance.yahoo.com

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BDTX Company Calendar

Last Earnings: 3/09/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BDTX
CUSIP: N/A
CIK: 1701541
Web: N/A
Phone: 617-252-0848
Fax: N/A
Employees: 86
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -69.30%
Return on Assets: -51.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.40
Quick Ratio: 8.40

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.69 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 36,510,000
Free Float: 33,201,000
Market Cap: $67.15 million
Optionable: Not Optionable
Beta: 1.87

Key Executives

Dr. David M. Epstein Ph.D. (Age 63)
Co-Founder, Pres, CEO & Director
Comp: $854.73k

Dr. Fang Ni Pharm.D. (Age 35)
CFO, Principal Financial Officer and Chief Bus. Officer
Comp: $639.23k

Mr. Brent Hatzis-Schoch Esq. (Age 57)
J.D., COO & Gen. Counsel
Comp: $610.48k

Dr. Elizabeth Buck Ph.D. (Age 47)
Co-Founder & Chief Scientific Officer

Ms. Erika Jones (Age 37)
VP of Fin., Corp. Controller & Principal Accounting Officer

Ms. Elizabeth L. Montgomery (Age 50)
Chief People Officer

Dr. Christopher D. Roberts Ph.D. (Age 52)
Advisor

Mr. Tai-An Lin Ph.D.
Sr. VP of Translational Science & Discovery Biology

Dr. Sergey Yurasov M.D. (Age 53)
Ph.D., Chief Medical Officer

Ms. Melanie Morrison
Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BDTX Stock - Frequently Asked Questions

How have BDTX shares performed in 2023?: Black Diamond Therapeutics' stock was trading at $1.80 on January 1st, 2023. Since then, BDTX shares have increased by 2.2% and is now trading at $1.8393.
View the best growth stocks for 2023 here.
When is Black Diamond Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BDTX earnings forecast.
How were Black Diamond Therapeutics' earnings last quarter?: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its quarterly earnings results on Thursday, March, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04.
What other stocks do shareholders of Black Diamond Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).
When did Black Diamond Therapeutics IPO?: (BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Black Diamond Therapeutics' stock symbol?: Black Diamond Therapeutics trades on the NASDAQ under the ticker symbol "BDTX."
Who are Black Diamond Therapeutics' major shareholders?: Black Diamond Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (3.26%), BlackRock Inc. (2.07%), Two Sigma Advisers LP (0.48%), Two Sigma Investments LP (0.30%), Dimensional Fund Advisors LP (0.07%) and Federated Hermes Inc. (0.04%). Insiders that own company stock include Bradley J Phd Bolzon, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni, Growth N V Biotech, Robert Alexander Ingram, Thomas Leggett and Versant Venture Capital Vi, L.
View institutional ownership trends.
How do I buy shares of Black Diamond Therapeutics?: Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Black Diamond Therapeutics' stock price today?: One share of BDTX stock can currently be purchased for approximately $1.84.
How much money does Black Diamond Therapeutics make?: Black Diamond Therapeutics (NASDAQ:BDTX) has a market capitalization of $67.15 million. The company earns $-91,170,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.
How can I contact Black Diamond Therapeutics?: Black Diamond Therapeutics' mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-252-0848 or via email at investors@bdtherapeutics.com.

This page (NASDAQ:BDTX) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial